Published by:
Tariq R, et al. Poster 1871: Durability and outcomes of fecal microbiota transplantation for recurrentC. difficileinfection in patients with moderate to severe inflammatory bowel disease. Presented at: Digestive Disease Week; May 5-9, 2023; Chicago (hybrid meeting).
Read nextC. difficileinfection recurrence after FMT higher than previously reported in IBD
Published by:
Tariq R, et al. Poster 1871: Durability and outcomes of fecal microbiota transplantation for recurrentC. difficileinfection in patients with moderate to severe inflammatory bowel disease. Presented at: Digestive Disease Week; May 5-9, 2023; Chicago (hybrid meeting).
Click Here to Manage Email Alerts
CHICAGO — More than 20% of patients with inflammatory bowel disease experiencedrecurrentClostridioidesdifficileinfection1 year after fecal microbiota transplantation, according to data presented at Digestive Disease Week.
“While there are data on the short-term efficacy ofFMT for eradicatingC.diffinfectionsin patients with IBD, there is less known about longer-term outcomes,”医学博士爱德华诉Loftus Jr .)the Maxine and Jack Zarrow Family Professor of Gastroenterology at the Mayo Clinic, told Healio. “We assessed our experience with longer follow-up time, focused our attention on patients with moderate to severe colonic IBD activity and found that the recurrence rate ofC.diffinfection was higher than previously reported, and that about one-third of patients ultimately required colectomy.”
Aiming to assess durability of FMT in patients with moderate to severe IBD, Loftus and colleagues conducted a retrospective study of 53 patients with IBD (median duration, 6 years; 36 ulcerative colitis; 14 ileocolonic Crohn’s disease; 3 indeterminate colitis) who were undergoing FMT via colonoscopy for recurrentC. difficileinfection.
Researchers collected data on demographics, IBD and recurrentC. difficileinfection history and post-FMT outcomes. Durability of FMT, which was defined being free fromC. difficileinfection recurrence at the 1-year follow-up, served as the primary outcome. Other outcomes included adverse events from FMT and colectomy rate.
According to researchers, 20 patients had moderate endoscopic severity when FMT was performed and 33 had severe. Before FMT, the median number ofC. difficileinfection episodes was three, with recurrentC. difficileinfection reported in 12 patients through the 1-year follow-up. The overall durable response was 74.4% (95% CI, 68.9-88).
Of the 12 patients with recurrence following the first FMT, 10 repeated the procedure and two were treated with antibiotics. Seven participants had an IBD flare, of whom two needed an emergency visit and one needed a colectomy; the remaining 46 patients reported no adverse events.
Loftus and colleagues noted 75% of patients had ongoing IBD flare at the time of FMT, with 80% continuing to flare after the procedure. Following FMT, 11.3% of participants experienced improvement in symptoms and 9% had a new flare. Notably, 84% had escalation of IBD therapy, but even with this, 38% required colectomy within a maximum follow-up of 8.2 years.
Univariate analysis also demonstrated thatC. difficileinfection after FMT was an independent predictor of colectomy risk (HR = 2.96; 95% CI, 1.04-8.46).
Loftus added, “The next step would be to investigate whether other microbial-derived therapies could decrease the colectomy rate in these [IBD-C. difficileinfection] patients.”
Read more about
Click Here to Manage Email Alerts
